Obalon Therapeutics Inc. | Income Statement
Fiscal year is January-December. All values USD Thousands.
2014
2015
2016
2017
2018
Sales/Revenue
3,539.00
4,039.00
3,393.00
9,914.00
9,101
Cost of Goods Sold (COGS) incl. D&A
2,912.00
2,503.00
2,809.00
4,829.00
5,423
Gross Income
627.00
1,536.00
584.00
5,085.00
3,678
SG&A Expense
10,467.00
16,469.00
20,089.00
37,576.00
40,643
EBIT
9,840.00
14,933.00
19,505.00
32,491.00
36,965
Unusual Expense
167.00
34.00
466.00
1,900.00
-
Non Operating Income/Expense
3.00
41.00
19.00
239.00
189
Interest Expense
220.00
549.00
477.00
135.00
226
Pretax Income
9,890.00
15,557.00
20,467.00
34,765.00
37,380
Consolidated Net Income
9,890.00
15,557.00
20,467.00
34,765.00
37,380
Net Income
9,890.00
15,557.00
20,467.00
34,765.00
37,380
Net Income After Extraordinaries
9,890.00
15,557.00
20,467.00
34,765.00
37,380
Net Income Available to Common
9,890.00
15,557.00
20,467.00
34,765.00
37,380
EPS (Basic)
0.59
0.93
4.85
2.08
1.96
Basic Shares Outstanding
16,703.50
16,703.50
4,221.90
16,717.10
19,036.70
EPS (Diluted)
0.59
0.93
4.85
2.08
1.96
Diluted Shares Outstanding
16,703.50
16,703.50
4,221.90
16,717.10
19,036.70
EBITDA
9,674.00
14,766.00
19,313.00
32,161.00
36,384
About Obalon Therapeutics
View Profile
